Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Google Scholar
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Google Scholar
Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in cancer immunotherapy. Nat. Rev. Cancer 23, 295–316 (2023).
Google Scholar
Emens, L. A. et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 81, 116–129 (2017).
Google Scholar
Chow, A., Perica, K., Klebanoff, C. A. & Wolchok, J. D. Clinical implications of T cell exhaustion for cancer immunotherapy. Nat. Rev. Clin. Oncol. 19, 775–790 (2022).
Google Scholar
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
Google Scholar
Lin, M. J. et al. Cancer vaccines: the next immunotherapy frontier. Nat. Cancer 3, 911–926 (2022).
Google Scholar
Kirchhammer, N., Trefny, M. P., Maur, P. A. D., Läubli, H. & Zippelius, A. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. Sci. Transl. Med. 14, eabo3605 (2022).
Google Scholar
Miller, C. L. et al. Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chem. Biol. 29, 451–462 (2022).
Google Scholar
Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, 33–43 (2017).
Google Scholar
Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Google Scholar
Dieu-Nosjean, M. C. et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008).
Google Scholar
Lee, Y. et al. Recruitment and activation of naive T cells in the islets by lymphotoxin β receptor-dependent tertiary lymphoid structure. Immunity 25, 499–509 (2006).
Google Scholar
Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).
Google Scholar
Heras-Murillo, I., Adán-Barrientos, I., Galán, M., Wculek, S. K. & Sancho, D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257–277 (2024).
Google Scholar
Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).
Google Scholar
Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).
Google Scholar
Meier, S. L., Satpathy, A. T. & Wells, D. K. Bystander T cells in cancer immunology and therapy. Nat. Cancer 3, 143–155 (2022).
Google Scholar
Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
Google Scholar
Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138–143 (2021).
Google Scholar
Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).
Google Scholar
Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298–312 (2021).
Google Scholar
Zimmermannova, O. et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci. Immunol. 8, eadd4817 (2023).
Google Scholar
Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).
Google Scholar
Zhu, Y. et al. Bioorthogonal cleavage chemistry: harnessing the bond-break reactions for biomolecule manipulations in living systems. Chin. J. Chem. 43, 553–566 (2025).
Dong, J. J., Krasnova, L., Finn, M. G. & Sharpless, K. B. Sulfur(VI) fluoride exchange (SuFEx): another good reaction for click chemistry. Angew. Chem. Int. Edn 53, 9430–9448 (2014).
Google Scholar
Wang, N. X. et al. Genetically encoding fluorosulfate-L-tyrosine to react with lysine, histidine, and tyrosine via SuFEx in proteins. J. Am. Chem. Soc. 140, 4995–4999 (2018).
Google Scholar
Yu, B. et al. Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants. Chem 8, 2766–2783 (2022).
Google Scholar
Wang, L. & Schultz, P. G. Expanding the genetic code. Angew. Chem. Int. Edn 44, 34–66 (2005).
Google Scholar
Chin, J. W. Expanding and reprogramming the genetic code. Nature 550, 53–60 (2017).
Google Scholar
Cheng, Z. J. J. et al. Novel PD-1 blockade bioassay to assess therapeutic antibodies in PD-1 and PD-L1 immunotherapy programs. Cancer Res. 75, 5440 (2015).
Google Scholar
Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557–569 (2012).
Google Scholar
Rodríguez-Silvestre, P. et al. Perforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells. Science 380, 1258–1265 (2023).
Google Scholar
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487–500 (2022).
Google Scholar
Jin, M. Z. & Wang, X. P. Immunogenic cell death-based cancer vaccines. Front. Immunol. 12, 697964 (2021).
Google Scholar
Oba, T. et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat. Commun. 11, 5415 (2020).
Google Scholar
Vescovini, R. et al. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J. Immunol. 179, 4283–4291 (2007).
Google Scholar
Lin, F. et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell 187, 7470–7491 (2024).
Google Scholar
Shalhout, S. Z., Miller, D. M., Emerick, K. S. & Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat. Rev. Clin. Oncol. 20, 160–177 (2023).
Google Scholar
Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689–706 (2019).
Google Scholar
Wang, G. et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11, 1395 (2020).
Google Scholar
Chen, Y. X. et al. An oncolytic virus–T cell chimera for cancer immunotherapy. Nat. Biotechnol. 42, 1876–1887 (2024).
Google Scholar
Chen, X. Y. et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat. Cancer 5, 1063–1081 (2024).
Google Scholar
Cruz, F. M., Chan, A. M. D. & Rock, K. L. Pathways of MHC I cross-presentation of exogenous antigens. Semin. Immunol. 66, 101729 (2023).
Google Scholar
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Google Scholar
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Google Scholar
Zhou, Y. X., Teng, P., Montgomery, N. T., Li, X. L. & Tang, W. P. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Cent. Sci. 7, 499–506 (2021).
Google Scholar
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593–598 (2021).
Google Scholar
Zhang, H. et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J. Am. Chem. Soc. 143, 16377–16382 (2021).
Google Scholar
Sefrin, J. P. et al. Sensitization of tumors for attack by virus-specific CD8+ T-cells through antibody-mediated delivery of immunogenic T-cell epitopes. Front. Immunol. 10, 1962 (2019).
Google Scholar
Millar, D. G. et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat. Biotechnol. 38, 420–425 (2020).
Google Scholar
van der Wulp, W. et al. Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells. Front. Immunol. 14, 1183914 (2023).
Google Scholar
Zimmermannova, O., Caiado, I., Ferreira, A. G. & Pereira, C. F. Cell fate reprogramming in the era of cancer immunotherapy. Front. Immunol. 12, 714822 (2021).
Google Scholar
Rapino, F. et al. C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity. Cell Rep. 3, 1153–1163 (2013).
Google Scholar
McClellan, J. S., Dove, C., Gentles, A. J., Ryan, C. E. & Majeti, R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc. Natl Acad. Sci. USA 112, 4074–4079 (2015).
Google Scholar
Linde, M. H. et al. Reprogramming cancer into antigen-presenting cells as a novel immunotherapy. Cancer Discov. 13, 1164–1185 (2023).
Google Scholar
Wang, J. L., Sun, S. C. & Deng, H. K. Chemical reprogramming for cell fate manipulation methods, applications, and perspectives. Cell Stem Cell 30, 1130–1147 (2023).
Google Scholar
Guan, J. Y. et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605, 325–331 (2022).
Google Scholar
Hu, Y. Y. et al. Induction of mouse totipotent stem cells by a defined chemical cocktail. Nature 617, 792–797 (2023).
Google Scholar
Manjunath, N. et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J. Clin. Invest. 108, 871–878 (2001).
Google Scholar
Ge, Y. et al. Enzyme-mediated intercellular proximity labeling for detecting cell-cell interactions. J. Am. Chem. Soc. 141, 1833–1837 (2019).
Google Scholar
Yin, S. et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci. Transl. Med. 12, eaaz1723 (2020).
Google Scholar
Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598 (2018).
Google Scholar
Cattaneo, C. M. et al. Tumor organoid-T-cell coculture systems. Nat. Protoc. 15, 15–39 (2020).
Google Scholar
Yin, S. et al. Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell Stem Cell 31, 717–733 (2024).
Google Scholar
تنويه من موقعنا
تم جلب هذا المحتوى بشكل آلي من المصدر:
yalebnan.org
بتاريخ: 2026-01-07 22:16:00.
الآراء والمعلومات الواردة في هذا المقال لا تعبر بالضرورة عن رأي موقعنا والمسؤولية الكاملة تقع على عاتق المصدر الأصلي.
ملاحظة: قد يتم استخدام الترجمة الآلية في بعض الأحيان لتوفير هذا المحتوى.
